These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33253848)

  • 21. Contact dermatitis to minoxidil.
    Nagarajan H; Rai R
    Contact Dermatitis; 2021 Jan; 84(1):57. PubMed ID: 32700369
    [No Abstract]   [Full Text] [Related]  

  • 22. Piggyback-acquired hypertrichosis.
    Farsani TT; Kane MJ; Kane KS
    Pediatr Dermatol; 2014; 31(4):520-2. PubMed ID: 24915767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Controversies in the treatment of androgenetic alopecia: The history of finasteride.
    Andy G; John M; Mirna S; Rachita D; Michael K; Maja K; Aseem S; Zeljana B
    Dermatol Ther; 2019 Mar; 32(2):e12647. PubMed ID: 30253001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.
    Jimenez-Cauhe J; Saceda-Corralo D; Rodrigues-Barata R; Moreno-Arrones OM; Ortega-Quijano D; Fernandez-Nieto D; Jaen-Olasolo P; Vaño-Galvan S
    Dermatol Ther; 2020 Nov; 33(6):e14106. PubMed ID: 32757405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Infantile generalized hypertrichosis caused by topical minoxidil.
    Rampon G; Henkin C; de Souza PR; Almeida HL
    An Bras Dermatol; 2016; 91(1):87-8. PubMed ID: 26982785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral minoxidil treatment for hair loss: A review of efficacy and safety.
    Randolph M; Tosti A
    J Am Acad Dermatol; 2021 Mar; 84(3):737-746. PubMed ID: 32622136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series.
    Beach RA; McDonald KA; Muylaert Barrett B
    J Am Acad Dermatol; 2021 Mar; 84(3):761-763. PubMed ID: 33098962
    [No Abstract]   [Full Text] [Related]  

  • 28. Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy.
    Beach RA
    Dermatol Ther; 2018 Nov; 31(6):e12707. PubMed ID: 30246901
    [No Abstract]   [Full Text] [Related]  

  • 29. Sensitization to saw palmetto and minoxidil in separate topical extemporaneous treatments for androgenetic alopecia.
    Sinclair RD; Mallari RS; Tate B
    Australas J Dermatol; 2002 Nov; 43(4):311-2. PubMed ID: 12423443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alopecia in congenital hidrotic ectodermal dysplasia responding to treatment with a combination of topical minoxidil and tretinoin.
    Melkote S; Dhurat RS; Palav A; Jerajani HR
    Int J Dermatol; 2009 Feb; 48(2):184-5. PubMed ID: 19200200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Androgenetic alopecia: drug treatment].
    Granel F
    Ann Dermatol Venereol; 2000 Jun; 127 Suppl 1():1S16-20. PubMed ID: 10962364
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-pulsed Nd:YAG laser in the treatment of facial hypertrichosis during topical minoxidil therapy.
    Benmously Mlika R; Ben Hamida M; Hammami H; Dorbani Ben Thabet I; Rouatbi M; Mokhtar I
    J Cosmet Laser Ther; 2013 Aug; 15(4):217-8. PubMed ID: 23463948
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of topical minoxidil therapy for androgenetic alopecia in women.
    Jacobs JP; Szpunar CA; Warner ML
    Int J Dermatol; 1993 Oct; 32(10):758-62. PubMed ID: 8225725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-Label Use of Topical Minoxidil in Alopecia: A Review.
    Stoehr JR; Choi JN; Colavincenzo M; Vanderweil S
    Am J Clin Dermatol; 2019 Apr; 20(2):237-250. PubMed ID: 30604379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erosive pustular dermatosis of the scalp from topical minoxidil 5% solution.
    Guarneri C; Cannavò SP
    Int J Dermatol; 2013 Apr; 52(4):507-9. PubMed ID: 22040279
    [No Abstract]   [Full Text] [Related]  

  • 36. Androgenetic alopecia in the female. Treatment with 2% topical minoxidil solution.
    DeVillez RL; Jacobs JP; Szpunar CA; Warner ML
    Arch Dermatol; 1994 Mar; 130(3):303-7. PubMed ID: 8129407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, investigator-blinded, controlled, split-scalp study of the efficacy and safety of a 1550-nm fractional erbium-glass laser, used in combination with topical 5% minoxidil versus 5% minoxidil alone, for the treatment of androgenetic alopecia.
    Suchonwanit P; Rojhirunsakool S; Khunkhet S
    Lasers Med Sci; 2019 Dec; 34(9):1857-1864. PubMed ID: 30982177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
    Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and cardiovascular tolerability of minotricon in the treatment of seborrheic alopecia].
    Rigoni C; Pinelli S; Toffolo P; Scarabelli G; Terenzio C
    G Ital Dermatol Venereol; 1990 Oct; 125(10):XLVII-LIII. PubMed ID: 2150507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination oral minoxidil and spironolactone for the treatment of androgenetic alopecia in adolescent girls.
    Olamiju B; Craiglow BG
    J Am Acad Dermatol; 2021 Jun; 84(6):1689-1691. PubMed ID: 33333154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.